Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB

(GEN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/17/2019 07/18/2019 07/19/2019 07/22/2019 07/23/2019 Date
1216(c) 1227(c) 1219.5(c) 1221(c) 1214.5 Last
219 370 304 331 234 275 201 360 60 616 Volume
-0.29% +0.90% -0.61% +0.12% -0.53% Change
More quotes
Financials (DKK)
Sales 2019 4 573 M
EBIT 2019 2 263 M
Net income 2019 1 858 M
Finance 2019 7 848 M
Yield 2019 0,04%
Sales 2020 5 546 M
EBIT 2020 2 514 M
Net income 2020 2 083 M
Finance 2020 9 327 M
Yield 2020 0,06%
P/E ratio 2019 40,7x
P/E ratio 2020 36,4x
EV / Sales2019 15,6x
EV / Sales2020 12,6x
Capitalization 79 325 M
More Financials
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (57.6%); - income from research and development (22.7%); - other... 
Sector
Biotechnology & Medical Research
Calendar
08/14 | 11:00amEarnings Release
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
07/22Genmab Announces the Completion of its Initial Public Offering of American De..
GL
07/22MORGAN STANLEY : Genmab Announces Full Exercise of Underwriters' Over-Allotment ..
AQ
07/22GENMAB A/S : - Major Shareholder Announcement
AQ
07/19Major Shareholder Announcement
GL
07/19Genmab Announces Full Exercise of Underwriters' Over-Allotment Option in Init..
GL
07/19GENMAB : Announces Submission of Extension of Marketing Authorization to Europea..
AQ
07/18GENMAB : Prices its Initial Public Offering of American Depositary Shares in the..
AQ
07/17Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs..
GL
07/17GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2019
AQ
07/16Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2..
GL
More news
Analyst Recommendations on GENMAB
More recommendations
Stock Trading Strategies
GENMAB - 02/07
A good level to buy
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
07/22GILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
07/22GILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 345,00  DKK
Last Close Price 1 221,00  DKK
Spread / Highest target 39,2%
Spread / Average Target 10,2%
Spread / Lowest Target -25,5%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB14.24%11 920
GILEAD SCIENCES3.77%82 702
VERTEX PHARMACEUTICALS5.05%44 598
REGENERON PHARMACEUTICALS-20.61%32 544
SAREPTA THERAPEUTICS INC32.61%11 068
ARRAY BIOPHARMA INC227.30%10 372